Found 352 oncology trials
A listing of oncology medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
The research study is being conducted to develop a test to predict a common complication after lung transplant called primary graft dysfunction (PGD). Predicting PGD before using donor organs may help reduce deaths and improve outcomes of patients receiving a lung transplant in the future.
This is a substudy of an umbrella study (MK-3475-U1). Subjects will be enrolled to the screening protocol and then subsequently enrolled to one of the substudies. This substudy examines MK-4830 in combination with pembrolizumab in participants with PD-L1 positive NSCLC.
This is a Phase III, randomised, double-blind, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) in combination with oleclumab (MEDI9447) or durvalumab (MEDI4736) with monalizumab (IPH2201) in adults with locally advanced (Stage III), unresectable NSCLC, who have not progressed following platinum-based cCRT.
This is a phase 1 first in human, dose escalation trial in subjects with advanced pancreatic cancer previously treated with 5-Fluorouacil-based Chemotherapy but never exposed to therapeutic gemcitabine.
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabine in participants with triple negative breast cancer …
To evaluate the safety, tolerability, and recommended Phase 2 dose (RP2D) of magrolimab in combination with bevacizumab and FOLFIRI (5-fluorouracil [5-FU], irinotecan, and leucovorin [LV]) in previously treated patients with advanced inoperable metastatic colorectal cancer (mCRC). We would like to rely on Advarra as the IRB of record for this …
This is a prospective, two arm, multicenter randomized open-label Phase III study evaluating the addition of 2 years of palbociclib to standard adjuvant endocrine therapy for patients with HR + / HER2- early breast cancer (EBC).
The study is being conducted to research if an investigational drug delivery system (gemcitabine/TAR-200) in combination with intravenous cetrelimab and intravenous cetrelimab alone can improve the results of radical cystectomy for participants with muscle invasive bladder cancer.
The intention of the study is to demonstrate superiority of AZD5305 + physician's choice NHA relative to placebo + physician's choice NHA by assessment of radiographic progression-free survival (rPFS) in participants with mCSPC.
This study will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib), in participants with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer who have developed resistance to adjuvant endocrine therapy. …
